The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Your Contributions (include, but are not limited to): Strategically leads the development, implementation, and continuous improvement of non-GxP and GxP system projects (e.g., LIMS, ELN, Modeling & Design, Business Intelligence, domain-specific AI/ML) for sophisticated data acquisition, tracking, processing, integration, and advanced analytics, including AI/ML enablement and adoption, encompassing evaluation of technical requirements for groundbreaking software system initiatives.